Security record · archived quarter
CLDX
Celldex Therapeutics, Inc. · Healthcare · Biotechnology
1Tracked holders
0Δ holders
444.92KShares held
$14.42MReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 444.92K | $14.42M | n/a | n/a |
| Q2 2026 | 87 | +8 | 50.70M | $1.89B | +11 | −3 |
| Q1 2026 | 82 | +10 | 42.54M | $1.35B | +12 | −2 |
| Q4 2025 | 72 | 0 | 42.78M | $1.16B | n/a | n/a |
| Q3 2025 | 17 | 0 | 35.45M | $917.00M | n/a | n/a |
| Q2 2025 | 14 | 0 | 33.46M | $680.97M | n/a | n/a |
| Q1 2025 | 11 | -1 | 21.24M | $385.48M | n/a | −1 |
| Q4 2024 | 12 | +1 | 21.78M | $550.46M | +2 | −1 |
| Q3 2024 | 10 | -1 | 17.69M | $601.30M | n/a | −1 |
| Q2 2024 | 11 | n/a | 17.48M | $646.94M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 444.92K | -71.8% | $14.42M | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 227 holders, 72.32M shares, $2.21B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API